Chrisly Dillon

MedicinePharmacology, Toxicology and PharmaceuticsEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy”.

Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy

American Journal of Kidney Diseases(2020)10.1053/j.ajkd.2020.09.018

N/A

0.104DataRank · unranked

1 citations

Rajbeer Singh Sangha, Chrisly Dillon, Todd M. Brown, Renuka Narayan, Mark Beasley +4 more

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

The Pharmacogenomics Journal(2020)10.1038/s41397-020-0162-5

N/A

0DataRank · unranked

46 citations

Larisa H. Cavallari, Craig R. Lee, William B. Hillegass, Ann Holmes, Todd C. Skaar +14 more

Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome

The American Journal of Cardiology(2021)10.1016/j.amjcard.2021.02.027

N/A

0DataRank · unranked

5 citations

Brittain Heindl, Anping Cai, Mark Beasley, Chrisly Dillon, Nita A. Limdi +2 more